In inoperable pleural mesothelioma, pemetrexed+ cisplatin as first line is considered the
standard of care, but novel treatments have been recently proposed. Our objective was to …

Opinion statement Systemic therapy is the only treatment option for the majority of
mesothelioma patients, for whom age, co-morbid medical illnesses, non-epithelial histology …

Systemic therapy options for patients with mesothelioma remain limited. Although many
conventional chemotherapeutic agents have shown modest activity in this disease, only the …

Background Pleural mesothelioma usually presents at an advanced, incurable stage.
Chemotherapy with platinum–pemetrexed is a standard treatment. We hypothesised that the …

Introduction Studies of bevacizumab and pembrolizumab in the treatment of malignant
pleural mesothelioma suggest anticancer efficacy; clinical trial populations are not reflective …

The management of pleural mesothelioma has changed with the demonstration that first-line
checkpoint blockade therapy improves survival. This review covers issues of relevance to …

Background Malignant pleural mesothelioma (MPM) is a locally aggressive disease with a
poor prognosis. After failure of first line platinum-based chemotherapy, there is no widely …

Introduction Malignant pleural mesothelioma (MPM) is an aggressive malignancy that affects
older adults with frequent comorbidities, making real-world treatment decisions challenging …

Introduction: Malignant mesothelioma is a rare and lethal malignancy primarily affecting the
pleura and peritoneum. Mesothelioma incidence is expected to increase worldwide and …

Opinion statement Mesothelioma is a rare and severe form of cancer that is associated with
asbestos exposure. Approximately 2500 Americans die annually from this condition with a …